These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 17105511

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B, MANIF 2000 Study Group.
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [Abstract] [Full Text] [Related]

  • 3. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
    Golub ET, Benning L, Sharma A, Gandhi M, Cohen MH, Young M, Gange SJ.
    Clin Infect Dis; 2008 Jan 15; 46(2):305-12. PubMed ID: 18171267
    [Abstract] [Full Text] [Related]

  • 4. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour.
    Smit C, Lindenburg K, Geskus RB, Brinkman K, Coutinho RA, Prins M.
    Addiction; 2006 Mar 15; 101(3):433-40. PubMed ID: 16499516
    [Abstract] [Full Text] [Related]

  • 5. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.
    HIV Med; 2007 Mar 15; 8(2):75-9. PubMed ID: 17352762
    [Abstract] [Full Text] [Related]

  • 6. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
    Chaix ML, Desquilbet L, Descamps D, Costagliola D, Deveau C, Galimand J, Goujard C, Signori-Schmuck A, Schneider V, Tamalet C, Pellegrin I, Wirden M, Masquelier B, Brun-Vezinet F, Rouzioux C, Meyer L, French PRIMO Cohort Study Group (ANRS CO 06), French ANRS AC11 Resistance Study Group.
    Antivir Ther; 2007 Mar 15; 12(8):1305-10. PubMed ID: 18240870
    [Abstract] [Full Text] [Related]

  • 7. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users.
    Tun W, Gange SJ, Vlahov D, Strathdee SA, Celentano DD.
    Clin Infect Dis; 2004 Apr 15; 38(8):1167-74. PubMed ID: 15095224
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.
    BMC Pediatr; 2007 Mar 17; 7():13. PubMed ID: 17367540
    [Abstract] [Full Text] [Related]

  • 10. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L.
    HIV Med; 2007 May 17; 8(4):213-9. PubMed ID: 17461848
    [Abstract] [Full Text] [Related]

  • 11. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.
    Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, Montaner JS.
    AIDS; 2007 Mar 30; 21(6):685-92. PubMed ID: 17413689
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
    Taha TE, Kumwenda J, Cole SR, Hoover DR, Kafulafula G, Fowler MG, Thigpen MC, Li Q, Kumwenda NI, Mofenson L.
    J Infect Dis; 2009 Nov 15; 200(10):1490-7. PubMed ID: 19832114
    [Abstract] [Full Text] [Related]

  • 14. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR, Pediatric AIDS Clinical Trials Group 219/219C Study Team.
    Clin Infect Dis; 2008 Feb 15; 46(4):507-15. PubMed ID: 18199042
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH, Weis N, Skinhøj P, Laursen A, Christensen PB, Nielsen HI, Møller A, Engsig F, Sørensen HT, Obel N.
    HIV Med; 2008 May 15; 9(5):300-6. PubMed ID: 18400077
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Heterogeneous response to HAART across a diverse population of people living with HIV: results from the ANRS-EN12-VESPA Study.
    Dray-Spira R, Spire B, Heard I, Lert F, VESPA Study Group.
    AIDS; 2007 Jan 15; 21 Suppl 1():S5-12. PubMed ID: 17159588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.